Dr. Clay B. Siegall: Fighting Cancer Through New ADC Technology

Clay B. Siegall, Ph.D. is known for having co-founded Seattle Genetics, Inc. in 1998. He is a scientist by training and serves as a board member of several biotechnology companies and other scientific organizations. He earned a Bachelor of Science (B.S.) in Zoology from the University of Maryland in College Park MD. He then went on to earn a Doctor of Philosophy (Ph.D.) in Genetics at George Washington University located in Washington, D.C.

After college, Siegall worked for a number of biotechnology, pharmaceutical and genomics companies including PDL Biopharma, MedImmune, Genentech, and the Curagen Corporation. He also served the U.S. government with stints at the National Cancer Institute and the National Institutes of Health which are part of the U.S. Department of Health and Human Services. From 1991 to 1997 Siegall worked for the pharmaceutical company Bristol-Myers Squibb.

Dr. Siegall founded Seattle Genetics  in 1998. He put his years of training to work to ensure that his company did quality work in the scientific community. He has been a leader in cultivating antibody-drug conjugates (ADCs) which are potent biopharmaceutical drugs used to treat cancer. He successfully secured FDA approval for his first ADC drug, Adcetris, in 2011. Seattle Genetics collaborated with the Takeda Pharmaceutical Company to make Adcetris a global brand accessible to people around the world.

Under the leadership of Dr. Siegall, Seattle Genetics now has many strategic licenses for dealing with its ADC technology. He has agreements with a number of companies including AbbVie, Genentech (Roche), Pfizer, and GlaxoSmithKline. So far these collaborations have made over $325 million. Currently there are over 20 ADCs undergoing clinical development using the technology created by Seattle Genetics. Plus, Dr. Siegall leads the fund raising activities of his company. Through both private and public financings, the company has secured over $1.2 billion.

Dr. Siegall has served on the boards of several companies such as Ultragenyx Pharmaceutical, Mirna Therapeutics, Inc., Alder Biopharmaceuticals Inc., and the Washington Roundtable. He has also been given several awards including the University of Maryland’s Alumnus of the Year for Computer, Math and Natural Sciences (2013) and the Entrepreneur of the Year (2012) issued by the Pacific Northwest Ernst & Young organization. Dr. Siegall is also the author of over 70 publications and he also holds 15 patents.